Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03893787 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| PF-03893787 5 mg | EXPERIMENTAL | - |
| PF-03893787 15 mg | EXPERIMENTAL | - |
| PF-03893787 50 mg | EXPERIMENTAL | - |
| PF-03893787 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Montelukast | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-03893787 | DRUG | oral solution, 5 mg, QD for 14 days |
| Placebo | DRUG | Oral, two doses 12 hours apart |
| Montelukast | DRUG | Oral, two doses 12 hours apart |
Inclusion Criteria: * Healthy male subjects and females of non-childbearing potential between the ages of 18 and 55 years. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m\^2; and a total body weight \>50 kg (110 lbs). Exclusion Criteria: * Evidence or history of clinically significant hematological,...
PF-03893787 is an investigational small molecule being developed by Pfizer for respiratory conditions, specifically studied in asthma and in healthy volunteers. It has been evaluated in Phase 1 clinical trials to assess its effect on lung function following an allergen challenge in asthmatic subjects and to evaluate its safety and tolerability in healthy adults.
PF-03893787 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for respiratory indications.
PF-03893787 is in Phase 1 clinical development. It has completed two Phase 1 trials, one in healthy volunteers and one in asthmatic subjects. The drug is investigational and has not been approved by regulatory authorities.
PF-03893787 has been studied in two completed Phase 1 trials. NCT00856687 assessed its effect on lung function following an allergen challenge in asthmatic subjects in the United Kingdom. NCT00992342 evaluated the safety and tolerability of different doses in healthy adult volunteers in Belgium.
PF-03893787 is the primary name for this investigational compound. No alternative names have been reported for this drug in the available clinical trial information. It is identified solely by its Pfizer code number in the studies.